SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring ...
SAN DIEGO, March 28, 2017 /PRNewswire/ -- Prometheus Laboratories Inc.—a Nestlé Health Science company—announces the launch of IBcause™, an all-in-one convenient test that evaluates a unique ...
Prometheus Launches the First Serogenetic Test to Predict Risk of Complications From Crohn's Disease
SAN DIEGO, Aug. 31 Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the commercial launch of its proprietary PROMETHEUS® Crohn's Prognostic test. This ...
When dosing is optimized, biologics such as IFX are highly effective for managing CD and UC. Anser IFX testing uses a drug-tolerant homogeneous mobility shift assay (HMSA) to provide clinicians ...
Translational Data Inform a Scalable, Noninvasive Test Designed to Identify Treatment-Eligible Patients and Enable Longitudinal Assessment as MASH Therapies Expand Prometheus has been at the forefront ...
SAN DIEGO, CA / ACCESS Newswire / April 1, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision-guided medicine, announces a new Anser ® therapeutic drug monitoring (TDM) test for ...
SAN DIEGO, CA / ACCESSWIRE / May 9, 2024 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision medicine for immune-mediated diseases, announced the execution of provider agreements with ...
SAN DIEGO, Aug. 21 Prometheus Laboratories Inc. announcedthe issuance of U.S. Patent No. 7,361,733, "Compositions and Methods for theTherapy and Diagnosis of Inflammatory Bowel Disease" which protects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results